Los Angeles Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $887K | Sell |
99,046
-2,332
| -2% | -$20.9K | ﹤0.01% | 678 |
|
|
2025
Q1 | $760K | Buy |
101,378
+190
| +0.2% | +$1.43K | ﹤0.01% | 641 |
|
|
2024
Q4 | $761K | Buy |
101,188
+14,655
| +17% | +$110K | ﹤0.01% | 705 |
|
|
2024
Q3 | $658K | Sell |
86,533
-11,044
| -11% | -$83.9K | ﹤0.01% | 785 |
|
|
2024
Q2 | $603K | Buy |
97,577
+7,963
| +9% | +$49.2K | ﹤0.01% | 806 |
|
|
2024
Q1 | $455K | Buy |
89,614
+36,284
| +68% | +$184K | ﹤0.01% | 903 |
|
|
2023
Q4 | $319K | Buy |
53,330
+20,202
| +61% | +$121K | ﹤0.01% | 1000 |
|
|
2023
Q3 | $235K | Buy |
33,128
+506
| +2% | +$3.58K | ﹤0.01% | 1031 |
|
|
2023
Q2 | $230K | Buy |
+32,622
| New | +$230K | ﹤0.01% | 1086 |
|
|
2022
Q4 | – | Sell |
-14,285
| Closed | -$180K | – | 1192 |
|
|
2022
Q3 | $180K | Buy |
+14,285
| New | +$180K | ﹤0.01% | 1180 |
|
|
2021
Q2 | – | Sell |
-30,950
| Closed | -$315K | – | 1540 |
|
|
2021
Q1 | $315K | Sell |
30,950
-147,375
| -83% | -$1.5M | ﹤0.01% | 1417 |
|
|
2020
Q4 | $1.33M | Buy |
178,325
+48,855
| +38% | +$364K | 0.01% | 812 |
|
|
2020
Q3 | $445K | Buy |
129,470
+46,515
| +56% | +$160K | ﹤0.01% | 1128 |
|
|
2020
Q2 | $395K | Sell |
82,955
-36,225
| -30% | -$172K | ﹤0.01% | 1197 |
|
|
2020
Q1 | $238K | Buy |
119,180
+30,130
| +34% | +$60.2K | ﹤0.01% | 1130 |
|
|
2019
Q4 | $307K | Buy |
+89,050
| New | +$307K | ﹤0.01% | 1124 |
|
|
2017
Q4 | – | Sell |
-25,170
| Closed | -$132K | – | 1318 |
|
|
2017
Q3 | $132K | Buy |
+25,170
| New | +$132K | ﹤0.01% | 1276 |
|
|
2015
Q2 | – | Sell |
-12,860
| Closed | -$116K | – | 1206 |
|
|
2015
Q1 | $116K | Buy |
+12,860
| New | +$116K | ﹤0.01% | 1187 |
|